Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Depression, Treatment Resistant Clear all
Completed Not applicable Interventional Results available

Vagal Nerve Stimulation for Treatment Resistant Major Depression

NCT04990687
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
gammaCore™
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression

NCT00953745
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Aripiprazole, Placebo Capsule, Placebo Tablet
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

A Study in Relapse Prevention of Treatment-Resistant Depression

NCT00958568
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Olanzapine and Fluoxetine combination (OFC), Fluoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
36
States / cities
Pasadena, California • Sherman Oaks, California • Wildomar, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Sep 17, 2026, 5:15 AM EDT
Withdrawn Not applicable Interventional

An Open Label Study of the Genecept™ Assay in Treatment Resistant Depression

NCT01438242
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Genecept Assay
Device
Lead sponsor
Genomind, LLC
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chalfont, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional

Brain Stimulation for Severe Depression

NCT05393622
View directory record Official record
Conditions
Depression Severe
Interventions
INTRACALVARIAL PREFRONTAL CORTICAL STIMULATION (IpCS) IN SEVERE TREATMENT-RESISTANT DEPRESSION
Device
Lead sponsor
Inner Cosmos Inc
Industry
Eligibility
21 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

Ketamine For Suicidal Ideation

NCT01507181
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional

rTMS to Target Neural Connectivity and Rumination in Treatment-Resistant Depression

NCT06511544
View directory record Official record
Conditions
Depression, Treatment Resistant
Interventions
Transcranial magnetic stimulation
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Nuedexta in Treatment-Resistant Major Depression

NCT01882829
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant
Interventions
dextromethorphan/quinidine
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

Development of Neuro-Navigated Transcranial Magnetic Stimulation (TMS) Using MRI

NCT05598931
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Soterix Medical
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

Treatment Resistant Depression (Pilot)

NCT01179009
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Ketamine, Clonidine, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Sep 17, 2026, 5:15 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Intravenous Ketamine Effects on Functional Neuroanatomy

NCT04205890
View directory record Official record
Conditions
Depression
Interventions
Ketamine
Drug
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional

RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)

NCT05531591
View directory record Official record
Conditions
Depression, Dementia, Mild Cognitive Impairment, Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression, Geriatric Depression
Interventions
Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion, Lithium Augmentation, Switch to nortriptyline
Drug
Lead sponsor
Centre for Addiction and Mental Health
Other
Eligibility
60 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Los Angeles, California • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

NCT06511908
View directory record Official record
Conditions
Suicide, Depressive Disorder, Treatment-Resistant, Ketamine, Molecular Mechanisms of Pharmacological Action, Neurotransmitter Agents, Excitatory Amino Acid Agents, Physiological Effects of Drugs, Depressive Disorder, Major, Depressive Disorder, Depression, Mental Disorders, Mood Disorders, Behavioral Symptoms
Interventions
(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg), Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of Riluzole in Treatment Resistant Depression

NCT01204918
View directory record Official record
Conditions
Depression
Interventions
Riluzole, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
New Haven, Connecticut • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance

NCT00835120
View directory record Official record
Conditions
Metabolic Syndrome, Bipolar Depression, Insulin Resistance
Interventions
Pioglitazone
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Withdrawn Phase 4 Interventional

Risperidone (Risperdal) Augmentation in Depressed Partial Responders to SRI Treatment

NCT00178854
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Risperidone
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional

Treatment Resistant Depression and Insomnia in Older Veterans

NCT02971150
View directory record Official record
Conditions
Treatment Resistant Depression, Insomnia
Interventions
Brief Behavioral Treatment for Insomnia
Behavioral
Lead sponsor
VA Pittsburgh Healthcare System
Federal
Eligibility
60 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

NCT05066672
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
NV-5138, matched placebo
Drug
Lead sponsor
Navitor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

NCT02493868
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
53
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Ketamine for Depression and Suicide Risk

NCT02094898
View directory record Official record
Conditions
Depression, Suicide
Interventions
Ketamine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 4 Interventional

Use of Risperidone in ECT for Treatment Resistant Depression

NCT00203723
View directory record Official record
Conditions
Major Depression
Interventions
Risperidone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 89 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 17, 2006 · Synced Sep 17, 2026, 5:15 AM EDT
Active, not recruiting Phase 2 Interventional

Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

NCT05838560
View directory record Official record
Conditions
Schizophrenia, Treatment Resistant Depression, Aging, Premature
Interventions
Dasatinib, quercetin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Withdrawn Phase 4 Interventional

Cannabidiol for Treatment Resistant Depression

NCT04732169
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Active study drug ( oral CBD), matching placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Treatment Resistant Geriatric Depression in Primary Care

NCT01392287
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Memantine
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
55 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 17, 2026, 5:15 AM EDT